104 related articles for article (PubMed ID: 33462186)
1. Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Constantin D; Widmann C
Cell Death Dis; 2021 Jan; 12(1):96. PubMed ID: 33462186
[No Abstract] [Full Text] [Related]
2. ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Constantin D; Widmann C
Cell Death Dis; 2020 Nov; 11(11):1019. PubMed ID: 33257682
[TBL] [Abstract][Full Text] [Related]
3. Primary testicular non-Hodgkin's lymphoma--a review article.
Bhatia K; Vaid AK; Gupta S; Doval DC; Talwar V
Sao Paulo Med J; 2007 Sep; 125(5):286-8. PubMed ID: 18094896
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
5. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
6. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
7. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.
Kaldor JM; Day NE; Band P; Choi NW; Clarke EA; Coleman MP; Hakama M; Koch M; Langmark F; Neal FE
Int J Cancer; 1987 May; 39(5):571-85. PubMed ID: 3570550
[TBL] [Abstract][Full Text] [Related]
8. Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy.
O'Flaherty C; Vaisheva F; Hales BF; Chan P; Robaire B
Hum Reprod; 2008 May; 23(5):1044-52. PubMed ID: 18346994
[TBL] [Abstract][Full Text] [Related]
9. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
11. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
12. Sternal Hodgkin's lymphoma: A case report and review of literature.
Yin YY; Zhao N; Yang B; Xin H
World J Clin Cases; 2020 Feb; 8(3):638-644. PubMed ID: 32110677
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
14. Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma.
Botchan A; Hauser R; Gamzu R; Yogev L; Lessing JB; Paz G; Yavetz H
Hum Reprod; 1997 Jan; 12(1):73-6. PubMed ID: 9043906
[TBL] [Abstract][Full Text] [Related]
15. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
[TBL] [Abstract][Full Text] [Related]
16. Classical Hodgkin's lymphoma presenting as a testicular mass: report of a case.
Seliem RM; Chikwava K; Swerdlow SH; Young RH; Ferry JA
Int J Surg Pathol; 2007 Apr; 15(2):207-12. PubMed ID: 17478785
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of immunoglobulin production by tumor cells in non-Hodgkin's and Hodgkin's malignant lymphomas and its significance for their classification.
Stein H; Papadimitriou CS; Bouman H; Lennert K; Fuchs J
Recent Results Cancer Res; 1978; 64():158-75. PubMed ID: 366694
[TBL] [Abstract][Full Text] [Related]
18. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
19. [Non-Hodgkin's lymphoma secondary to Hodgkin's disease treated with chemo- and radiotherapy. Report of a case].
Gamboa Domínguez A; Pita Ramírez L; Hurtado Monroy R; Angeles-Angeles A
Rev Invest Clin; 1992; 44(3):393-8. PubMed ID: 1283228
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin-induced flagellate erythema in a patient with Hodgkin's lymphoma - A case report and review of literature.
Vennepureddy A; Siddique MN; Odaimi M; Terjanian T
J Oncol Pharm Pract; 2016 Jun; 22(3):556-60. PubMed ID: 25855241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
